

Reporting period January – September

- ◆ **Orders received** increased by 15.7% to SEK 13,809 million (11,933), corresponding to organic growth of 8.0%
- ◆ **Orders received for the quarter** increased by 15.8% to SEK 4,624 million (3,993), corresponding to organic growth of 10.2%
- ◆ **Net sales** rose by 13.8% to SEK 12,849 million (11,288)
- ◆ **Profit before tax** increased by 24.7% to SEK 1,089 million (873)
- ◆ **Net profit** increased by 26.5% to SEK 784 million (620)
- ◆ **Earnings per share** increased by 26.4% to SEK 3.73 (2.96)
- ◆ **EBITA before restructuring** rose by 27.8% to SEK 2,020 million (1,581)
- ◆ **Continued strong earnings outlook for the year.**
- ◆ **Public offer for Datascope Corp.**
- ◆ **Increased new share issue creates financial flexibility.**

Third quarter 2008

Favourable demand, combined with an expanded market organisation and a strong product program, resulted in a good level of orders received, while the Group's operating margin improved according to plan. The offer for Datascope is an additional and key step in strengthening the Cardiovascular Division.

Orders received Orders received by the Group developed strongly during the quarter and increased organically by 10.2%. The cumulative organic growth in orders received for the first nine months of the year amounted to a full 8%.

For the Group in its entirety, orders received were good in all geographic regions and all business areas. Orders received in North America were particularly strong.

Results Consolidated profit before tax amounted to SEK 334 million (221), an increase of 51.1% compared with the third quarter of 2007. Profit before tax was charged with restructuring and integration expenses of SEK 28 million (110). EBITA excluding restructuring expenses amounted to SEK 631 million (500), an increase of 26.2%, compared with the same period last year. EBITA margin amounted to 14.7%, an improvement of 1.7 percentage points compared with the same quarter last year. The earnings improvement for the period is largely attributable to earnings contributions from the newly acquired Cardiac and Vascular Surgery divisions as well as synergy gains in the wake of the Huntleigh integration.

Negative exchange-rate effects impacted on the quarter's earnings in an amount of SEK 61 million.

Both Medical Systems and Extended Care reported good profit growth and improved EBITA margins in line with established targets. For Infection Control, EBITA declined as a result of a higher cost level according to plan.

The Group's operating cash flow amounted to SEK 604 million (698). For the first nine months of the year the operating cash flow thus amounted to SEK 2,316 million (2,010). During the quarter, inventory levels increased in preparation for planned and major deliveries during the fourth quarter of the year.

Outlook

Demand for the Group's products remains positive. A somewhat weaker demand in parts of the European market is offset by continued positive growth in North America and in several emerging markets. The Group's order book remains at a good level.

Medical Systems is expected to report organic invoicing growth that exceeds market growth. This growth is stimulated by several product launches as well as the ongoing gradual expansion of the business area's market organisation. Competitiveness was strengthened as a result of continued investments in new production capacity in China and Turkey.

The Cardiac and Vascular Surgery divisions, which are consolidated within the Group from the start of the current year, performed very well and continue to contribute to the Group's earnings before tax and to strengthening EBITA margin for both the Group and the business area.

The acquisition of Datascope Corp, which is estimated to be finalised around the end of the year and consolidated into the Group's accounts from the beginning of next year, will contribute to the Group's earnings before tax from 2010 as a result of good synergy gains.

Extended Care anticipates improved volume growth during the current year. Several product launches have contributed to this improved growth. Earnings synergies connected with the Huntleigh acquisition are another contributing factor to volume growth. The EBITA margin is improving significantly as a result of realised synergy gains and declining restructuring costs.

Infection Control also anticipates positive volume growth. Strengthening in terms of products and market also contribute to growth. Investments in new markets and an improved business area management will ensure long-term profitability and growth, but will be charged against the business area's earnings and operating margin in the short term.

Exchange-rate fluctuations will have a negative impact on this year's earnings.

Restructuring costs in the wake of the Huntleigh integration and the acquisition of the Cardiac and Vascular Surgery divisions are estimated to amount to approximately SEK 220 million for this year, which is approximately SEK 15 million more than previously announced. The increased integration costs reflect some decisions that have been

brought forward and will result in a reduction of integration costs for 2009 in a corresponding amount.

The development during the quarter did not result in any revision of the Group's earnings outlook for the year. A weaker earnings growth within Infection Control is offset by better performance in Extended Care and Medical Systems. The Group continues to anticipate organic invoicing growth in line with the 2007 level, while the EBITA margin continues to strengthen, even excluding the Cardiac and Vascular Surgery divisions, which are expected to contribute to earnings before tax already in the current year.

Business area Medical Systems

Orders received

Orders received per market	2008	2007	<i>Change adjusted for</i>	2008	2007	<i>Change adjusted for</i>
	Q 3	Q 3	<i>curr.flucs.&corp.acqs.</i>	9 Mon	9 Mon	<i>curr.flucs.&corp.acqs.</i>
Europe	940	814	11.0%	2 814	2 466	10.2%
USA and Canada	590	246	14.5%	1 768	757	6.4%
Asia and Australia	348	261	18.4%	924	741	9.5%
Rest of the world	131	119	4.6%	455	294	48.2%
Business area total	2 009	1 440	12.4%	5 961	4 258	12,0%

Orders received for the business area continue to develop very well and increased organically by 12.4% in the period.

In Europe, orders received rose organically by 11.0% with increases in basically all sub-markets.

In the North American market, growth was highly satisfactory in all product areas, including Critical Care, which started the year on a weak note.

In emerging markets, orders received were generally very good, particularly in South-East Asia.

Results

	2008	2007	<i>Change</i>	2008	2007	<i>Change</i>	2007
	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales, SEK million	1 844	1 445	27.6%	5 486	4 130	32.8%	6 079
<i>adjusted for currency flucs. & corp.acqs</i>			-0.2%			4.1%	
Gross profit	1 025	726	41.2%	3 126	2 154	45.1%	3 112
<i>Gross margin %</i>	55.6%	50.2%	5.4%	57.0%	52.2%	4.8%	51.2%
Operating cost, SEK million	-737	-522	41.2%	-2 256	-1 532	47.3%	-2 079
EBITA before restructuring and integration costs	337	205	64.4%	1 011	627	61.2%	1 040
<i>EBITA margin %</i>	18.3%	14.2%	4.1%	18.4%	15.2%	3.2%	17.1%
Restructuring and integration costs	-14	-		-59	-		-
EBIT	274	204	34.3%	811	622	30.4%	1 033
<i>EBIT margin %</i>	14.9%	14.1%	0.8%	14.8%	15.1%	-0.3%	17.0%

EBITA before restructuring costs for the period amounted to SEK 337 million (205), an increase of 64.4%. Restructuring costs connected to the integration of the Cardiac and Vascular Surgery divisions amounted to SEK 14 million. The improved earnings were primarily attributable to the continued strong earnings in the acquired Cardiac and Vascular Surgery divisions, while other operations within the business area performed well.

The EBITA margin for the quarter amounted to 18.3%, an improvement of 4.1 percentage points compared with last year.

Activities

Integration of the Cardiac and Vascular Surgery divisions

The integration of the Cardiac and Vascular Surgery divisions, which were acquired from Boston Scientific and were consolidated into the Group's accounts from the beginning of this year, is progressing very well.

With regard to revenue synergies, the business area continues to estimate that these will lead to the new Cardiovascular division achieving sustainable organic growth of 10% from 2010. Sales-related synergies will partly comprise the acquired operations' products being distributed through the business area's existing market channels outside the US and partly comprise Medical Systems' Perfusion products being distributed through the acquired company's strong market organisation in the US.

Cost-related synergies are expected to amount to SEK 100 – 120 million from 2010. These synergies will partly be realised through the optimisation of the administration structure and partly through the discontinuation of the production unit in Dorado in Puerto Rico, with relocation to the plant in Wayne, New Jersey.

The total non-recurring costs for realising the above-mentioned synergies are expected to amount to SEK 85 million, of which approximately SEK 70 million will be charged against the current year.

Acquisition of Datascope Corp

On 15 September this year, Getinge submitted a public offer for the US company, Datascope Corp. The offer of USD 53 per share values Datascope at a so called enterprise value of USD 616 million.

Through the acquisition of Datascope, Getinge will significantly strengthen its product range within the prioritised Cardiovascular division. Datascope has sales of USD 231 million, 765 employees, is global leader within the Cardiac Assist area and has more than 70% of the global market for Intra Aortic Balloon Pumping. Datascope also has a very attractive product portfolio within vascular surgery and the area of vascular intervention with synthetic vessel graft and endovascular stent products that well complement the business area's existing vascular surgery programme.

Getinge estimates that the acquisition of Datascope will lead to significant earnings synergies in the coming year. Datascope's product programme as well as the company's geographic coverage highly complements Medical Systems' existing products and market organisation. The acquisition will also generate opportunities for increased efficiency in the organisation. On the whole, the Group estimates that the acquisition will contribute to the Group's profit before tax from 2010, including amortisation of acquisition-related surplus value and acquisition financing.

The acquisition of Datascope is conditional upon the customary approval from authorities and is estimated to be finalised during the latter part of this year.

Cardiohelp

In November this year, Medical Systems will launch its new cardiac assist product, CARDIOHELP, (formerly ELS, Emergency Life Support). CARDIOHELP is an assist product that temporarily takes over the heart and/or lung functions to ensure the survival of the patient or provide the heart or lungs the opportunity to recover. The product is intended for use within emergency cardiac care in, for example, rescue vehicles and within intensive care for the treatment of patients with highly reduced lung capacity (ARDS - Adult Respiratory Distress Syndrome). CARDIOHELP is also assessed to have major potential within intervention cardiology (catheter-based heart procedures). CARDIOHELP is portable, weighs only about 10 kg and consists of a user-friendly console and patient-specific disposable product. The product has already been used in emergency situations and has treated several patients with life-threatening conditions with excellent results. In July this year, CARDIOHELP (ELS) was approved and certified by the European Aviation Safety Agency (EASA), and is thus the first cardio assist product to be approved for in-flight use. CARDIOHELP is estimated to have major market potential and interest from opinion builders and the medical profession is significant.

Flow-i

The product launching of Medical Systems' new anaesthesia product program, Flow-i, is progressing according to plan and the business area expects to launch the new product program in connection with the ESA conference in June 2009 in Milan, Italy.

Business area Extended Care

Orders received

	2008	2007	Change adjusted for	2008	2007	Change adjusted for
Orders received per market	Q 3	Q 3	<i>curr.flucs.&corp.acqs.</i>	9 Mon	9 Mon	<i>curr.flucs.&corp.acqs.</i>
Europe	829	910	0.5%	2 714	2 732	3.5%
USA and Canada	524	430	31.3%	1 337	1 228	14.3%
Asia and Australia	128	139	-1.9%	413	358	9.5%
Rest of the world	43	28	67.2%	99	95	10.1%
Business area total	1 524	1 507	10.6%	4 563	4 413	7.2%

Extended Care's orders received increased organically by 10.6% during the quarter. The strong orders received must be compared with the strong quarter last year. Both wound care and patient management areas developed well.

In the European market, volume growth was mixed with good growth in Southern and Eastern Europe. In Scandinavia and the German-speaking markets, volumes declined somewhat while other markets were in line with last year.

In North America, orders received increased significantly in both the US and Canada. Large orders for patient handling equipment were received from the Veterans Association in the US.

Results

	2008	2007	Change	2008	2007	Change	2007
	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales, SEK million	1 441	1 432	0.6%	4 344	4 274	16%	6 009
<i>adjusted for currency flucs. & corp.acqs</i>			10.4%			5.5%	
Gross profit	642	631	1.7%	2 065	1 957	5.5%	2 775
Gross margin %	44.6%	44.1%	0.5%	47.5%	45.8%	1.7%	46.2%
Operating cost, SEK million	-463	-481	-3.7%	-1 442	-1 433	0.6%	-1 894
EBITA before restructuring and integration costs	207	182	13.7%	708	610	16.1%	998
EBITA margin %	14.4%	12.7%	1.7%	16.3%	14.3%	2.0%	16.6%
Restructuring and integration costs	-13	-109		-85	-229		-257
EBIT	166	41	304.9%	538	295	82.4%	624
EBIT margin %	11.5%	2.9%	8.6%	12.4%	6.9%	5.5%	10.4%

Extended Care's EBITA before restructuring costs, amounted to SEK 207 million (182), an increase of 13.7%. The EBITA margin amounted to 14.4%, which corresponds to a margin improvement of 1.7 percentage points. A significant portion of the earnings improvement was attributable to the cost synergies in connection with the Huntleigh acquisition.

Restructuring costs amounted to SEK 13 million for the period, compared with SEK 109 million last year.

Activities

Integration of Huntleigh

At the end of this, the third quarter of the year, the structural integration of Huntleigh is largely completed. During the quarter, the business area's plant in Suzhou, China, commenced operations, which facilitates the implementation of the final phase of production rationalisation. The new plant in China will take over the remaining production from Luton in the UK in terms of the business area's pump console manufacturing for compressor mattresses and DVT products. The production relocation will be finalised before the end of the year.

With regard to the integration of Huntleigh's and Extended Care's sales companies, this activity is also largely completed. During the quarter, the sales companies in Australia, the Netherlands and Ireland were merged.

To sum up, the structural integration of Huntleigh has proceeded better than expected and the cost-related synergies announced in connection with the acquisition of more than SEK 300 million will be realised.

Since the middle of this year, more focus has been put on achieving the earnings-related synergies that will ensure that the business area's organic volume growth will stabilise at around 7% from next year, as previously communicated. Major training of the business area's sales team and new integrated customer offerings are a vital and ongoing activity to ensure goal achievement.

Product development and launches

The business area continues to develop new products in line with previously announced ambitions to launch 15 to 20 new products or larger product upgrades this year. One of the newly launched products during the quarter is the Hot Track ceiling hoist. Compared with most ceiling hoists in the market, which must be removed from the rails in the ceiling and connected with a socket for charging, Hot Track is charged by a continuous flow of electricity to the ceiling rail. Accordingly, it is not necessary to remove the hoist from the ceiling rail and this avoids unnecessary and heavy lifts and the risk that the hoist cannot be used because it is not charged.

For many years, the patient hoist, Maxi Move, has been the business area's most important product in terms of sales. Through the "new" Maxi Move, Extended Care is launching a platform-based replacement with increased and improved functionality and greater competitiveness.

Business area Infection Control

Orders received

Orders received per market	2008	2007	<i>Change adjusted for</i>	2008	2007	<i>Change adjusted for</i>
	Q 3	Q 3	<i>curr.flucs.&corp.acqs.</i>	9 Mon	9 Mon	<i>curr.flucs.&corp.acqs.</i>
Europe	569	552	3.7%	1 744	1 824	-3.9%
USA and Canada	331	329	7.6%	983	974	10.6%
Asia and Australia	155	148	4.0%	424	389	8.7%
Rest of the world	36	16	121.5%	135	75	80.4%
Business area total	1 091	1 045	6.8%	3 286	3 262	3.9%

Orders received by the business area increased by 6.8% during the period. As in other business areas, orders received during the corresponding quarter last year were very good.

In the European market, growth was good in the UK, in German-speaking markets and in Benelux. In other regions in Europe, orders received were in line with the corresponding quarter last year or somewhat lower.

In North America, orders received remained strong. Investments in hospital renovations and new construction remain at a good level.

Orders received in emerging markets were generally at a good level.

Results

	2008	2007	<i>Change</i>	2008	2007	<i>Change</i>	2007
	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales, SEK million	1 006	967	4.0%	3 018	2 884	4.6%	4 357
<i>adjusted for currency flucs. & corp.acqs</i>			6.5%			8.1%	
Gross profit	354	347	2.0%	1 106	1 080	2.4%	1 659
<i>Gross margin %</i>	35.2%	35.9%	-0.7%	36.6%	37.4%	-0.8%	38.1%
Operating cost, SEK million	-270	-237	13.9%	-816	-748	9.1%	-1 034
EBITA before restructuring and integration costs	87	113	-23.0%	301	343	-12.2%	640
<i>EBITA margin %</i>	8.6%	11.7%	-3.1%	10.0%	11.9%	-19%	14.7%
Restructuring and integration costs	-1	-		-3	-		-
EBIT	83	110	-24.5%	287	332	-13.6%	625
<i>EBIT margin %</i>	8.3%	11.4%	-3.1%	9.5%	11.5%	-2.0%	14.3%

The business area's EBITA amounted to SEK 87 million (113), which is a decrease of 23%. The EBITA margin decreased by 3.1 percentage points to 8.6%. The decline in the result was primarily an effect of the continued investments made in the expansion of the business area's management function and market organisation to strengthen growth and profitability in the long term.

Activities

Acquisition of Subtil Crepieux

After the end of the reporting period, the business area signed a binding agreement for the acquisition of Subtil Crepieux, which is one of the business area's larger competitors in the French market. The acquisition pertains mainly to the company's service organization and relating net assets as well as the right to Subtil Crepieux trade mark. The acquired operation had sales during the past fiscal year of approximately EUR 3.6 million with very satisfactory profitability.

The acquisition does not pertain to the manufacture of sterilisation equipment, which is currently operated by the seller and which the seller has undertaken to discontinue. Through the acquisition, Infection Control will be able to increase its market share in France in the service market. The purchase consideration amounted to approximately EUR 3.3 million and corresponds to an EBITDA multiple of 2.8 times. The acquisition will contribute to the business area's and the Group's profit from 2009.

New markets

The business area continues to increase its exposure in markets with strong growth potential and during the period an additional sales office was opened in Xian, China.

Product launches

During the quarter, the business area launched a new insulation product. ISOCYT Freja, which is manufactured by the French company La Calhène, is the most recent addition to the ISOCYT family. In pace with the increase in the number of cancer patients, hospitals need to adapt their formulation and production environments to be able to safely handle hazardous substances used in chemotherapy. ISOCYT Freja guarantees the safety of employees and patients.

Other information

Accounting This interim report was prepared for the Group in accordance with the IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company in accordance with the Swedish Annual Accounts Act. The accounting and calculation principles used in the interim report are identical to those used in the most recent annual report.

Nomination committee for the 2009 Annual General Meeting In accordance with the resolution at the 2005 Annual General Meeting of Getinge AB, the Nomination Committee comprises Getinge's Chairman of the Board as well as representatives of the five largest shareholders on 31 August and one representative of the smaller shareholders. For the 2009 Annual General Meeting, this means that Getinge's Nomination Committee will consist of: Carl Bennet, Carl Bennet AB; Marianne Nilsson, Swedbank Robur AB; Bo Selling, Alecta; Annika Andersson, Fjärde AP Fonden; Anders Oscarsson, SEB Wealth Management and Olle Törnblom, representative of the smaller shareholders.

Shareholders who want to submit proposals to Getinge's 2009 Nomination Committee may do so by e-mail at: valberedningen@getinge.com or by post at Getinge AB, Att: Nomination Committee, Box 69, SE-310 44 GETINGE.

Annual General Meeting Getinge AB's Annual General Meeting will be held on 21 April 2009 at 4:00 p.m. at Kongresshallen, Hotell Tylösand, Halmstad, Sweden. Shareholders who wish to have issues addressed at the General Meeting on 21 April 2009 must submit proposals to Getinge's Chairman of the Board by e-mail: arenden.bolagsstamma@getinge.com or write to Getinge AB, Att: Bolagsstämmoärenden, Box 69, SE-310 44 GETINGE. To ensure inclusion in the notice of the Meeting and subsequently the Meeting's agenda, proposals must arrive at the Company no later than Tuesday 3 March 2009.

New share issue The acquisition climate in several of Getinge's priority market areas is highly favourable at present. At the same time, volatility in currency markets has recently increased, which is affecting the amount of Getinge's net debt. In view of this, the Board of Directors proposes to expand the new share issue that was announced in conjunction with the acquisition of Datascope so that it will amount to approximately SEK 2 billion, of which approximately SEK 1 billion will continue to be used for the partial financing of the Datascope acquisition.

In the near future, the Board of Directors of Getinge intends to convene an Extraordinary General Meeting in mid-November 2008 to authorize the Board of Directors to make decisions concerning a rights issue

Carl Bennet AB, a company owned by Getinge AB's Chairman of the board, Carl Bennet, has declared that it will guarantee the new share issue in its entirety. Getinge intends to implement the new share issue during the fourth quarter of this year on condition that the acquisition of Datascope is finalised within this period.

Risk management Political decisions altering the healthcare reimbursement system represent the single greatest risk for the Getinge Group. The risk to the Group as a whole is limited by the fact that Getinge is active in a large number of countries. The Group's operational risks are limited since, as a

rule, its customers' operations are funded directly or indirectly by public funds. The Group's Risk Management Team works continuously to minimise the risk of production disruptions.

Financial risk management

Getinge is exposed to a number of financial risks in its operations. "Financial risks" refer primarily to risks related to currency and interest rates as well as credit risks. Risk management is regulated by a financial policy established by the Board of Directors. The ultimate responsibility for managing the Group's financial risks and developing methods and principles for financial-risk management lies with Group management and the treasury function. The main financial risks to which the Group is exposed are currency risks, interest-rate risks, and credit and counterparty risks.

Forward-looking Information

This report contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.

Next report

The next report from the Getinge Group (fourth quarter 2008) will be published on 26 January 2009.

Telephone Conference

The telephone conference will take place today at 2:00 p.m. Swedish time. To participate, please call:
Within Sweden +46 (0)8 506 269 04
Outside Sweden +44 (0)20 710 863 03

A recorded version of the conference will be available for five working days at the following number:
Sweden: +46 (0)8 506 269 49, Access code: 224266#

During the telephone conference, a presentation will be held. To gain access to this presentation, please click on the following link:
<https://www.anywhereconference.com/?Conference=108224266&PIN=518417>

The presentation is also available at: <http://www.getingegroup.com/>

The Board of Directors and CEO ensure that the interim report provides a true and fair overview of the Parent Company and the Group's operations, position and earnings and describes the material risks faced by the Parent Company and the Group.

Växjö, 16 October 2008

Carl Bennet
Chairman

Johan Bygge

Rolf Ekedahl

Jan Forslund

Carola Lemne

Margareta Norell Bergendahl

Bo Sehlin

Johan Stern

Johan Malmquist
CEO

Getinge AB
Box 69, SE-310 44 Getinge
Telephone: +46 (0)35-15 55 00.
Telefax: +46 (0)35-549 52
E-mail: info@getinge.com
Corporate Registration Number: 556408-5032
www.getingegroup.com

The information given here is information that Getinge AB is obligated to publish under the Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act.

Consolidated Income statement

	2008	2007	Change	2008	2007	Change	2007
SEK million	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales	4 290	3 844	11.6%	12 849	11 288	13.8%	16 445
Cost of goods sold	-2 268	-2 140	6.0%	-6 552	-6 097	7.5%	-8 899
Gross profit	2 022	1 704	8.7%	6 297	5 191	21.3%	7 546
<i>Gross margin</i>	47.1%	44.3%	2.8%	49.0%	46.0%	3.0%	45.9%
Selling expenses	-908	-775	17.2%	-2 808	-2 283	23.0%	-3 072
Administrative expenses	-443	-389	13.9%	-1 326	-1 174	12.9%	-1 604
Research & development costs ¹	-112	-85	31.8%	-373	-265	40.8%	-335
Restructuring and integration costs	-28	-110		-147	-230		-257
Other operating income and expenses	-7	8		-7	10		4
Operating profit ²	524	353	48.4%	1 636	1 249	31.0%	2 282
<i>Operating margin</i>	12.2%	9.2%	3.0%	12.7%	11.1%	1.6%	13.9%
Financial net	-190	-132		-547	-376		-507
Profit before tax	334	221	51.1%	1 089	873	24.7%	1 775
Taxes	-93	-64		-305	-253		-514
Net profit	241	157	53.5%	784	620	26.5%	1 261
Attributable to:							
Parent company's shareholders	240	157		782	620		1 260
Minority interest	1	—		2	—		1
Net profit	241	157		784	620		1 261
Earnings per share, SEK ³	1.12	0.73	53.4%	3.73	2.96	26.0%	5.97

¹ Development costs totalling SEK 305 million (210) have been capitalised during the year, of which SEK 98 million (68) were capitalised during the quarter.

² Operating profit is charged with

— amortisation intangibles on acquired companies	-79	-37		-237	-102		-139
— amortisation intangibles	-27	-21		-80	-55		-82
— depreciation other fixed assets	-127	-119		-371	-337		-463
	-233	-177		-688	-494		-684

³ New share issue registered on 15 April 2008. The key ratios per share for prior periods have been recalculated using the number of shares after the new share issue to achieve comparability between accounting periods.

Quarterly results

	2006	2006	2007	2007	2007	2007	2008	2008	2008
SEK million	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3
Net sales	2 883	3 995	3 415	4 029	3 844	5 157	4 107	4 452	4 290
Cost of goods sold	-1 618	-2 120	-1 751	-2 206	-2 140	-2 802	-2 031	-2 253	-2 268
Gross profit	1 265	1 875	1 664	1 823	1 704	2 355	2 076	2 199	2 022
Operating cost	-898	-1 035	-1 264	-1 327	-1 351	-1 322	-1 524	-1 639	-1 498
Operating profit	367	840	400	496	353	1 033	552	560	524
Financial net	-53	-52	-114	-130	-132	-131	-183	-174	-190
Profit before tax	314	788	286	366	221	902	369	386	334
Taxes	-85	-215	-83	-106	-64	-261	-104	-108	-93
Profit after tax	229	573	203	260	157	641	265	278	241

Consolidated Balance sheet

	2008	2007	2007
Assets SEK million	30 Sep	30 Sep	31 Dec
Intangible fixed assets	14 989	10 333	10 396
Tangible fixed assets	2 914	2 291	2 327
Financial assets	1 055	1 006	755
Stock-in-trade	3 950	3 089	2 913
Current receivables	5 689	4 462	5 706
Cash and cash equivalents	939	951	894
Total assets	29 536	22 132	22 991
Shareholders' equity & liabilities			
Shareholders' equity	8 085	6 060	6 623
Long-term liabilities	16 018	11 882	11 908
Current liabilities	5 433	4 190	4 460
Total equity & liabilities	29 536	22 132	22 991

Consolidated Cash flow statement

SEK million	2008 Q 3	2007 Q 3	2008 9 Mon	2007 9 Mon	2007 FY
<i>Current activities</i>					
Operating profit	524	353	1 636	1 249	2 282
Adjustment for non-cash items	231	245	772	622	761
Financial items	-190	-132	-547	-376	-507
Taxes paid	-114	-101	-470	-397	-528
Cash flow before changes in working capital	451	365	1 391	1 098	2 008
<i>Changes in working capital</i>					
Stock-in-trade	-185	-81	-652	-588	-341
Rental equipment	-60	-40	-139	-125	-168
Current receivables	-287	71	369	648	-458
Current operating liabilities	340	111	211	116	287
Cash flow from operations	259	426	1 180	1 149	1 328
<i>Investments</i>					
Acquisition of subsidiaries	-181	-	-5 074	-5 578	-5 622
Investments in intangible fixed assets	-112	-77	-333	-232	-348
Investments in tangible fixed assets	-178	-117	-427	-337	-467
Disposal of tangible fixed assets	3	10	14	17	34
Cash flow from investments	-468	-184	-5 820	-6 130	-6 403
<i>Financial activities</i>					
Change in interest-bearing debt	980	-240	4 173	4 427	4 518
Change in long-term receivables	-163	1	-148	1 231	1 249
New share issue	-	-	1 491	-	-
Dividend paid	-	-	-515	-444	-444
Cash flow from financial activities	817	-239	5 001	5 214	5 323
Cash flow for the period	608	3	361	233	248
Cash and cash equivalents at beginning of the year	1 081	843	894	673	673
Translation differences	-750	105	-316	45	-27
Cash and cash equivalents at end of the period	939	951	939	951	894

Operating cash flow statement

SEK million	2008 Q 3	2007 Q 3	2008 9 Mon	2007 9 Mon	2007 FY
Business activities					
Operating profit	524	353	1 636	1 249	2 282
Restructuring costs	28	110	147	230	257
Adjustment for non-cash items	244	173	744	480	695
	796	636	2 527	1 959	3 234
Changes in operating capital					
Stock-in-trade	-185	-81	-652	-588	-341
Rental equipment	-60	-40	-139	-125	-168
Current receivables	-287	71	369	648	-458
Current liabilities	340	112	211	116	287
Operating cash flow	604	698	2 316	2 010	2 554
Restructuring cost cash generated	-41	-37	-119	-87	-190
Operating cash flow after restructuring cost	563	661	2 197	1 923	2 364

Consolidated Net interest-bearing debt

SEK million	2008 30 Sep	2007 30 Sep	2007 31 Dec
Debt to credit institutions	13 650	9 313	9 454
Provisions for pensions, interest-bearing	1 823	1 923	1 805
Less liquid funds	-939	-951	-894
Net interest-bearing debt	14 534	10 285	10 365

Changes to shareholders' equity

SEK million	2008 30 Sep	2007 30 Sep	2007 31 Dec
Shareholders' equity – opening balance	6 623	6 005	6 005
Dividend distributed	-515	-444	-444
New share issue	1 491	–	–
Change of reserve hedge accounting	-140	-7	-58
Translation differences	-158	-114	-141
Net profit	784	620	1 261
Shareholders' equity – closing balance	8 085	6 060	6 623
Attributable to:			
Parent Company's shareholders	8 059	6 036	6 598
Minority interest	26	24	25
Total shareholders' equity	8 085	6 060	6 623

Key figures

	2008	2007	Change	2006	2008	2007	Change	2006	2007
	Q 3	Q 3		Q 3	9 Mon	9 Mon		9 Mon	FY
Orders received, SEK million	4 624	3 993	15.8%	2 988	13 809	11 933	15.7%	9 657	16 519
adjusted for currency flucs.& corp.acqs			10.2%				8.0%		
Net sales, SEK million	4 290	3 844	11.6%	2 883	12 849	11 288	13.8%	9 006	16 445
adjusted for currency flucs.& corp.acqs			5.4%				5.6%		
EBITA before restructuring and integration costs	631	500	26.2%	376	2 020	1 581	27.8%	1 170	2 678
EBITA margin before restructuring and integration costs	14.7%	13.0%	1.7%	13.0%	15.7%	14.0%	1.7%	13.0%	16.3%
Restructuring and integration costs	28	110		-	147	230		47	257
EBITA	603	390	54.6%	376	1 873	1 351	38.6%	1 123	2 421
EBITA margin	14.1%	10.1%	4.0%	13.0%	14.6%	12.0%	2.6%	12.5%	14.7%
Earnings per share after full tax, SEK *	1.12	0.73	53.4%	1.07	3.73	2.96	26.0%	3.28	5.98
Number of shares, thousands	214 491	201 874		201 874	209 610	201 874		201 874	201 874
Operating capital, SEK million					16 681	10 555	58.0%	10 133	10 778
Return on operating capital, percent					15.4%	19.4%	-4.0%	18.0%	19.7%
Return on equity, percent					20.9%	19.9%	1.0%	22.2%	20.3%
Net debt/equity ratio, m multiple					1.80	1.70	0.10	0.85	1.57
Interest cover, multiple					4.0	4.7	-0.7	8.7	4.3
Equity/assets ratio, percent					27.4%	27.4%	0.0%	38.4%	28.8%
Equity per share, SEK					37.57	29.90	25.7%	27.34	32.68
Number of employees at the end of the period					11 632	10 608	9.7%	7 428	10 358

* New share issue registered on 15 April 2008. The key ratios per share for prior periods have been recalculated using the number of shares after the new share issue to achieve comparability between accounting periods.

Income statement for the parent company

	2008	2007	2008	2007	2007
SEK million	Q 3	Q 3	9 Mon	9 Mon	FY
Administrative expenses	-19	-24	-65	-75	-67
Operating profit	-19	-24	-65	-75	-67
Financial net	-576	23	-422	59	542
Profit before tax	-595	-1	-487	-16	475
Taxes	165	-8	133	-7	96
Net profit	-430	-9	-354	-23	571

Balance sheet for the parent company

Assets	SEK million	2008	2007	2007
		30 Sep	30 Sep	31 Dec
Tangible fixed assets		11	13	12
Shares in Group companies		4 796	3 493	4 120
Long-term financial receivables		38	42	41
Deferred tax asset		86	-	86
Receivable from group companies		16 582	12 150	13 033
Short-term receivables		76	38	65
Total assets		21 589	15 736	17 357
Shareholders' equity & liabilities				
Shareholders' equity		4 315	3 173	3 829
Long-term liabilities		11 073	7 069	7 523
Current liabilities		6 201	5 494	6 005
Total equity & liabilities		21 589	15 736	17 357

Information pertaining to the Parent Company's development during the January - September 2008 reporting period

Income statement At the end of the period, receivables and liabilities in foreign currencies were valued at the closing-day rate and an unrealised loss of SEK 764 million is included in the year's net financial items.

Balance sheet During the first quarter of 2008, the Cardiac and Vascular Surgery divisions from Boston Scientifics were acquired at a purchase price of USD 750 million (SEK 4,851 million). The increase in the Parent Company's long-term liabilities is largely attributable to financing of the acquisition.

Companies acquired in 2008

Boston Scientific's Cardiac and Vascular Surgery divisions

In January 2008, Boston Scientific's Cardiac and Vascular Surgery divisions were acquired. The divisions operate within the areas of endoscopic vessel harvesting, anastomosis, stabilisers and instrument for surgery on beating hearts and vessel implants. The total acquisition price amounted to approximately USD 750 million (SEK 4,851). The acquisition was reported according to the acquisition method. Acquisition costs in conjunction with the acquisition amounted to SEK 45 million.

Acquired net assets and goodwill in connection with the acquisition

SEK million	Net Assets	Balance sheet at time of acquisition	Adjustments at fair value	Fair value
	Intangible assets	2	1 947	1 949
	Tangible fixed assets	351	45	396
	Stock-in-trade	163		163
	Other current assets	239		239
	Provisions	-170		-170
	Short-term liabilities	-138	-49	-187
		447	1 943	2 390
	Goodwill			2 461
	Total acquisition with cash and cash equivalents			4 851
	Net outflow of cash and cash equivalents due to acquisition			4 851

Goodwill arising in connection with the transaction is principally attributable to synergies in terms of customer relationship's, geography, production and sales and distribution.

The acquired divisions from Boston Scientific are included in Getinge's sales and operating profit from 1 January 2008.

It is not practical to disclose the profits for the acquired business from the acquisition date due to the integration work that has been conducted during the year.

Olmed AB

Medical Systems has acquired all the shares in Olmed AB, based in Dalby, Sweden. Olmed, which in 2007 had sales of slightly less than SEK 70 million, has been a distributor of Surgical Workplaces products since the beginning of the 1990s and has 10 employees. The acquisition of Olmed is in line with the Group's and the business area's strategy to own, to the largest possible extent, distribution channels in all key markets. Olmed, which is consolidated in the Group's accounts from 1 July 2008, is expected to contribute to the Group's earnings per share during 2008.

Acquired net assets and goodwill in connection with the acquisition

SEK million	Net Assets	Balance sheet at time of acquisition	Adjustments at fair value	Fair value
	Intangible assets	0	39	39
	Stock-in-trade	4		4
	Other current assets	2		2
	Provisions	-1		-1
	Short-term liabilities	-3		-3
		2	39	41
	Goodwill			28
	Total acquisition with cash and cash equivalents			69
	Net outflow of cash and cash equivalents due to acquisition			69

Goodwill arising in connection with the acquisition is attributable to additional sales of Medical Systems' products in Sweden.

Definitions

EBIT	Operating profit
EBITA	Operating profit before amortisation of intangible assets identified in conjunction with corporate acquisitions.
BRIC	Brazil, Russia, India, China

Review report

We have reviewed this report for the period 1 January 2008 to 30 September 2008 for Getinge AB (publ). The board of directors and the CEO are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

We conducted our review in accordance with the Swedish Standard on Review Engagements SÖG 2410, Review of Interim Report Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing in Sweden, RS, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company.

Malmö, 16 October 2008

Öhrlings PricewaterhouseCoopers AB

Magnus Willfors
Authorised Public Accountant
Auditor in charge

Johan Rippe
Authorised Public Accountant